Edition:
United States

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

19.65USD
19 Sep 2018
Change (% chg)

-- (--)
Prev Close
$19.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
140,008
52-wk High
$23.30
52-wk Low
$11.90

Latest Key Developments (Source: Significant Developments)

Vanda Pharmaceuticals Gets Paragraph IV Certification Notice For Generic Version Of Hetlioz Capsule
Monday, 26 Mar 2018 07:53am EDT 

March 26 (Reuters) - Teva Pharmaceutical Industries Ltd ::VANDA PHARMACEUTICALS - ON MARCH 23, GOT PARAGRAPH IV CERTIFICATION NOTICE LETTER REGARDING ANDA BY TEVA FOR GENERIC VERSION OF 20MG HETLIOZ CAPSULE.VANDA SAYS IN LETTER, TEVA ALLEGES SOME PATENTS WILL NOT BE INFRINGED BY ITS USE OR SALE OF 20MG HETLIOZ - SEC FILING.  Full Article

Vanda Pharma Prices Public Offering Of Common Stock
Thursday, 15 Mar 2018 07:46pm EDT 

March 15 (Reuters) - Vanda Pharmaceuticals Inc ::PRICES PUBLIC OFFERING OF COMMON STOCK.‍SALE OF 5.5 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING AT $17.00 PER SHARE​.  Full Article

Vanda Pharmaceuticals Inc. Proposes Public Offering Of Common Stock
Wednesday, 14 Mar 2018 04:01pm EDT 

March 14 (Reuters) - Vanda Pharmaceuticals Inc ::VANDA PHARMACEUTICALS INC. PROPOSES PUBLIC OFFERING OF COMMON STOCK.VANDA PHARMACEUTICALS INC - ‍NET PROCEEDS TO BE USED FOR COMMERCIAL AND RESEARCH AND DEVELOPMENT ACTIVITIES​.  Full Article

Vanda's Hetlioz Demonstrates Efficacy To Treat Jet Lag Disorder
Monday, 5 Mar 2018 07:00am EST 

March 5 (Reuters) - Vanda Pharmaceuticals Inc ::HETLIOZ® (TASIMELTEON) DEMONSTRATES EFFICACY TO TREAT JET LAG DISORDER IN AN 8 HOUR PHASE ADVANCE CLINICAL STUDY.VANDA PHARMACEUTICALS INC - ‍HETLIOZ DEMONSTRATED SIGNIFICANT AND CLINICALLY MEANINGFUL BENEFITS IN NIGHTTIME AND DAYTIME SYMPTOMS OF JET LAG DISORDER​.VANDA PHARMACEUTICALS - ‍RESULTS FROM JET8 STUDY SHOWED CLINICALLY MEANINGFUL EFFECTS OF HETLIOZ 20 MG ON PRIMARY ENDPOINT,MULTIPLE SECONDARY ENDPOINTS​.VANDA PHARMACEUTICALS INC - ‍INTENDS TO SEEK MARKETING APPROVAL FOR USE OF HETLIOZ IN TREATMENT OF JET LAG DISORDER​.VANDA PHARMACEUTICALS INC - ‍HETLIOZ DEMONSTRATES IMPROVEMENT IN TOTAL SLEEP TIME BY 85 MINUTES VERSUS PLACEBO IN STUDY​.VANDA PHARMACEUTICALS INC - ‍HETLIOZ DEMONSTRATES IMPROVEMENT IN NEXT DAY ALERTNESS VERSUS PLACEBO IN STUDY​.  Full Article

Vanda receives negative opinion for marketing authorization from the European Medicines Agency
Friday, 10 Nov 2017 04:05pm EST 

Nov 10 (Reuters) - Vanda Pharmaceuticals Inc ::Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia.Vanda Pharmaceuticals Inc - ‍CHMP re-examined its negative opinion and confirmed refusal of fanaptum MAA​.  Full Article

Vanda Pharmaceuticals posts qtrly ‍net loss of $0.10​/share
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Vanda Pharmaceuticals Inc :Qtrly ‍net loss per share $0.10​.  Full Article

Vanda Pharmaceuticals reached a pricing agreement with the German National Association of Statutory Health Insurance Funds
Wednesday, 18 Oct 2017 07:34am EDT 

Oct 18 (Reuters) - Vanda Pharmaceuticals Inc :Vanda Pharmaceuticals - On Oct 17, co reached a pricing agreement with the German National Association of Statutory Health Insurance Funds.Vanda Pharmaceuticals - Pricing agreement for treatment of totally blind individuals with sleep-wake disorder with Hetlioz after an arbitration board decision.Vanda Pharmaceuticals - ‍Ex-factory price of Hetlioz in Germany expected to be about eur 69,000/year, effective date of Aug 1, 2017​ - SEC Filing.  Full Article

Vanda Pharmaceuticals qtrly ‍net loss per share $0.03​
Wednesday, 2 Aug 2017 04:01pm EDT 

Aug 2 (Reuters) - Vanda Pharmaceuticals Inc :Vanda Pharmaceuticals Inc - ‍total net product sales were $42.1 million in Q2 of 2017​.Vanda Pharmaceuticals Inc - qtrly ‍net loss per share, basic and diluted $ 0.03​.Q2 earnings per share view $-0.28, revenue view $40.3 million -- Thomson Reuters I/B/E/S.Sees ‍2017 combined net product sales from both Hetlioz and Fanapt between $165 million to $175 million​.  Full Article

Vanda receives negative opinion for marketing authorization from the EMA on Fanaptum
Friday, 21 Jul 2017 07:00am EDT 

July 21 (Reuters) - Vanda Pharmaceuticals Inc :Vanda receives negative opinion for marketing authorization from the European Medicines Agency on Fanaptum™ for the treatment of schizophrenia.Vanda Pharmaceuticals Inc - ‍Vanda intends to appeal this opinion and request a re-examination by CHMP​.Vanda Pharmaceuticals Inc - ‍CHMP was of opinion that "benefits of Fanaptum did not outweigh its risks" and recommended against marketing authorization​.  Full Article

Armistice Capital Llc reports 5.1 pct passive stake in Vanda Pharmaceuticals Inc
Monday, 19 Jun 2017 04:46pm EDT 

June 19 (Reuters) - Vanda Pharmaceuticals Inc :Armistice Capital Llc reports a 5.1 percent passive stake in Vanda Pharmaceuticals Inc as of June 7 - sec filing.  Full Article